Unravelling the multi-target mechanism of methoxylated flavonoids in Parkinson's disease: Insights from network pharmacology and molecular dynamics
Toxicology Reports · 2026-06 · 16 · 102248
DOI: 10.1016/j.toxrep.2026.102248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology Reports, 2026-06. Verfasst von Chetan Ashok und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu 600116, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INTI International University, Sri Ramachandra Institute of Higher Education and Research.
Abstract (Originalsprache)
Current therapy for Parkinson's disease (PD), a neurodegenerative disorder that progresses over time marked by protein aggregation, dopaminergic neuronal death and oxidative stress, only provides symptomatic alleviation. By using an integrative computational strategy that combines molecular dynamics simulations, molecular docking and network pharmacology, this study sought for the investigation of the neuroprotective potential of methoxylated flavonoids (MFs). Drug-likeness and ADMET profiling of ten MFs revealed favorable pharmacokinetics, including good oral bioavailability and low predicted toxicity. Network pharmacology identified 172 putative targets, of which 118 overlapped with PD-associated genes, highlighting the multi-targeted nature of these compounds. Protein-protein interaction analysis revealed important hub proteins like HSP90AA1, MMP9, GSK-3β and AKT1 involved in neurodegeneration, oxidative stress regulation, and apoptotic signaling. Analysis of KEGG and GO pathway enrichment revealed significant modulation of the signaling pathway PI3K-Akt and the cellular elements necessary for neuronal survival and repair. Molecular docking revealed high-affinity interactions of Eupatilin and Norwogonin with key PD targets, particularly HSP90AA1 and MMP9. Molecular dynamics simulations confirmed the Eupatilin-HSP90AA1 complex's stability over a 100 ns period, indicating stable interactions and minimal conformational fluctuations. These findings suggest that methoxylated flavonoids possess multi-target therapeutic potential against PD, contributing to broader goals in public health and mental health by modulating interconnected neuroprotective pathways. However, as the results are predictive in nature, confirming their translational value requires experimental confirmation through in vitro and in vivo research. Study highlights Eupatilin as a potential lead substance for additional pharmacological research aimed at disease modification in Parkinson's disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu 600116, India.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, Karnataka 560054, India.
- Department of Pharmaceutical Regulatory Affairs and Management, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
- Department of Pharmacology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu 600116, India.
- Department of Pharmacology, Siddha Central Research Institute, Central Council for Research in Siddha, Anna Hospital Campus, Arumbakkam, Chennai 600106, India.
- Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Petaling Jaya, Selangor Darul Ehsan 47500, Malaysia.
Förderung
- INTI International University
- Sri Ramachandra Institute of Higher Education and Research
Zitieren
APA
Ashok, C., Jeyabalan, S., Pavadai, P., M, V., S, D. D. P., Mohan, D., Sugumar, R., Sugumar, R., Jabaris, S. L., Subramaniyan, V., Wong, L. S., & Sekar, M. (2026). Unravelling the multi-target mechanism of methoxylated flavonoids in Parkinson's disease: Insights from network pharmacology and molecular dynamics. Toxicology Reports, 16, 102248. https://doi.org/10.1016/j.toxrep.2026.102248
Vancouver
Ashok C, Jeyabalan S, Pavadai P, M V, S DDP, Mohan D, et al. Unravelling the multi-target mechanism of methoxylated flavonoids in Parkinson's disease: Insights from network pharmacology and molecular dynamics. Toxicology Reports. 2026;16:102248. doi:10.1016/j.toxrep.2026.102248
BibTeX
@article{Ashok2026,
author = {Ashok, Chetan and Jeyabalan, Srikanth and Pavadai, Parasuraman and M, Vignesh and S, Devaraja Dravida Pandiyan and Mohan, Durga and Sugumar, Revathi and Sugumar, Ramya and Jabaris, Sugin Lal and Subramaniyan, Vetriselvan and Wong, Ling Shing and Sekar, Mahendran},
title = {Unravelling the multi-target mechanism of methoxylated flavonoids in Parkinson's disease: Insights from network pharmacology and molecular dynamics},
journal = {Toxicology Reports},
year = {2026},
volume = {16},
pages = {102248},
doi = {10.1016/j.toxrep.2026.102248}
}
EUVIMED